Mirabegron for neurogenic detrusor overactivity in people aged 3 to 17 years

Mirabegron is currently in clinical development for treatment of neurogenic detrusor overactivity
(NDO) in children and adolescents aged 3 to 17 years old on clean intermittent catheterisation
(CIC). NDO is a bladder dysfunction and can cause urinary symptoms such as frequency, urgency
and urinary incontinence. Other symptoms of NDO include: pelvic pain, painful urination,
incontinence, increased spasticity, autonomic dysreflexia, malaise, fever/chills, nausea, headache.
Current treatment options for NDO in children and adolescent populations are very limited and
are not well-tolerated.